Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenus
257
316
171
187
195
213
Croissance des revenus (H/H)
-6%
85%
-9%
-4%
-8%
-10%
Coût des ventes
77
94
42
45
60
61
Bénéfice brut
179
221
129
142
135
151
Vente, Général et Administration
102
85
75
78
76
60
Recherche et développement
35
34
51
30
36
44
Frais d'exploitation
143
119
126
109
113
104
Autres revenus (charges) non opérationnels
5
-1
0
-8
0
--
Bénéfice avant impôts
29
61
-4
22
22
34
Charge d'impôt sur le revenu
17
25
4
10
7
2
Bénéfice net
12
35
-8
12
14
31
Croissance du bénéfice net
-45%
-538%
-167%
-14%
-55%
-39%
Actions en circulation (diluées)
13.2
13.1
13.1
13.8
14.1
15.3
Variation des actions (H-H)
3%
0%
-5%
-2%
-8%
-4%
EPS (dilué)
0.91
2.73
-0.66
0.87
1.01
2.09
Croissance du EPS
-49%
-514%
-176%
-14%
-52%
-36%
Flux de trésorerie libre
-9
50
27
48
55
52
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
69.64%
69.93%
75.43%
75.93%
69.23%
70.89%
Marge opérationnelle
14%
32.27%
1.16%
17.64%
10.76%
22.06%
Marge bénéficiaire
4.66%
11.07%
-4.67%
6.41%
7.17%
14.55%
Marge du flux de trésorerie libre
-3.5%
15.82%
15.78%
25.66%
28.2%
24.41%
EBITDA
56
114
5
36
25
50
Marge EBITDA
21.78%
36.07%
2.92%
19.25%
12.82%
23.47%
D&A pour le résultat opérationnel
20
12
3
3
4
3
EBIT
36
102
2
33
21
47
Marge EBIT
14%
32.27%
1.16%
17.64%
10.76%
22.06%
Taux d'imposition effectif
58.62%
40.98%
-100%
45.45%
31.81%
5.88%
Follow-Up Questions
Quels sont les états financiers clés de Eagle Pharmaceuticals Inc ?
Quels sont les ratios financiers clés pour EGRX ?
Comment les revenus de Eagle Pharmaceuticals Inc sont-ils répartis par segment ou géographie ?
Eagle Pharmaceuticals Inc est-elle rentable ?
Eagle Pharmaceuticals Inc a-t-elle des passifs ?
Combien d'actions en circulation Eagle Pharmaceuticals Inc a-t-elle ?
Statistiques clés
Clôture préc.
$0.25
Prix d'ouverture
$0.25
Plage de la journée
$0.25 - $0.25
Plage de 52 semaines
$0.1 - $3.87
Volume
200
Volume moyen
3.8K
BPA (TTM)
0.92
Rendement en dividend
--
Capitalisation boursière
$3.2M
Qu’est-ce que EGRX ?
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.